EMC Capital Management Raises Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

EMC Capital Management raised its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 142.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 44,535 shares of the company’s stock after acquiring an additional 26,134 shares during the quarter. EMC Capital Management’s holdings in Reviva Pharmaceuticals were worth $81,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after acquiring an additional 42,376 shares during the period. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Trading Up 2.7 %

NASDAQ RVPH opened at $1.89 on Friday. Reviva Pharmaceuticals Holdings, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $4.83. The stock has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $1.35.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RVPH. HC Wainwright lowered their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, January 21st. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Friday, January 10th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $11.40.

Reviva Pharmaceuticals Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.